AI Article Synopsis
- This study examined how tolvaptan affects metabolism and electrolyte balance in heart failure patients.
- After analyzing 16 studies, researchers found no significant difference in hyperuricemia incidence between those taking tolvaptan and those on a placebo.
- Tolvaptan significantly lowered blood uric acid levels compared to traditional diuretics, making it a potential alternative for heart failure patients at risk for gout.
Article Abstract
Background: This study aimed to investigate the effect of tolvaptan on metabolism and electrolyte homeostasis in patients with heart failure (HF).
Methods: Literature databases, such as PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, VIP, and WanFang Data, were systematically searched for relevant trials from inception to November 4, 2023. We used the fixed effect model to combine the effect sizes and used to test heterogeneity. Funnel plots were plotted to assess publication bias.
Results: 16 studies were eligible for further analysis. No significant differences were identified in the incidence of hyperuricemia between the tolvaptan group and the placebo group (odds ratio (OR) = 1.23, 95% confidence interval (CI) = 0.97 to 1.55, = 0.09). Tolvaptan decreased the levels of blood uric acid compared to traditional diuretics (mean difference (MD) = -82.8, 95% CI = -96.48 to -69.13, < 0.00001). There was no significant difference in hypernatremia (OR = 1.62, 95% CI = 0.66 to 3.96, = 0.29) and hyperkalemia (OR = 1.17, 95% CI = 0.93 to 1.48, = 0.18) between the tolvaptan and control groups.
Conclusions: Tolvaptan reduced the level of blood uric acid compared to conventional diuretics, and could be used as a substitute for traditional diuretics for HF patients with a high risk of gout.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440402 | PMC |
| http://dx.doi.org/10.31083/j.rcm2509334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[A novel carbonyl reductase for the synthesis of ()-tolvaptan].
Sheng Wu Gong Cheng Xue Bao
January 2025
Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, College of Chemistry and Materials Sciences, Hebei University, Baoding 071002, Hebei, China.
Screening carbonyl reductases with the ability to catalyze the reduction of complex carbonyl compounds is of great significance for the biosynthesis of -tolvaptan(-TVP). In this study, the target carbonyl reductase in the crude enzyme extract of rabbit liver was separated, purified, and identified by ammonium sulfate precipitation, gel-filtration chromatography, ion exchange chromatography, affinity chromatography, and protein mass spectrometry. With the rabbit liver genome as the template, the gene encoding the carbonyl reductase was amplified by PCR and the recombinant strain was successfully constructed.
View Article and Find Full Text PDFSafety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.
Front Pharmacol
January 2025
Department of Cardiology, Affiliated Changshu Hospital of Nantong University, Changshu, China.
Objective: This study aims to analyze the adverse drug events (ADEs) associated with tolvaptan in the Food and Drug Administration Adverse Event Reporting System database from the fourth quarter of 2009 to the second quarter of 2024.
Methods: After standardizing the data, various signal detection techniques, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network, and Multi-Item Gamma Poisson Shrinker, were employed for analysis.
Results: Among the 7,486 ADE reports where tolvaptan was the primary suspected drug, a total of 196 preferred terms were identified, spanning 24 different system organ classes.
Arginine vasopressin and angiotensin II coregulate Aquaporin 2 expression in M-1 cells.
Biochem Biophys Res Commun
January 2025
School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China; Anhui Provincial Key Laboratory of Chinese Medicinal Formula, Hefei, China; Institute for Pharmacodynamics and Safety Evaluation of Chinese Medicine, Anhui Academy of Chinese Medicine, Hefei, China. Electronic address:
Objective: The aim of this study was to explore the impact of arginine vasopressin (AVP) and angiotensin II (Ang II) on aquaporin 2 (AQP2) expression in M - 1 cells.
Methods: M - 1 cells were stimulated with desmopressin (dDAVP) and Ang II, followed by treatment with tolvaptan and losartan. The expression and protein levels of V2R, AT1R, AQP2, and p-S256AQP2 were measured via ELISA, western blotting, RT-qPCR, and immunofluorescence.
Efficacy and safety of low-dose tolvaptan (7.5mg) in the treatment of inpatient hyponatraemia: a retrospective study.
Endocr Pract
December 2024
Department of Endocrinology, King's College Hospital NHS Foundation Trust, London, United Kingdom. Electronic address:
Objectives: The recommended dose of tolvaptan for hyponatraemia secondary to SIADH is 15mg. We evaluated the efficacy of an initial 7.5mg dose and determined the frequency where sodium (Na+) correction exceeded safe limits, defined as an increment of ≥10 mmol/L, within the initial 8 or 24 hours of administration.
View Article and Find Full Text PDFEvaluating the safety and effectiveness of tolvaptan in patients with heart failure and renal impairment: a systematic review and meta-analysis.
Eur J Clin Pharmacol
February 2025
North Devon District Hospital, Barnstaple, North Devon, UK.
Purpose: Patients with heart failure and concomitant renal impairment are often prescribed loop diuretics, such as furosemide, as the primary treatment. The present meta-analysis is focused on analyzing the safety and efficacy of the implementation of tolvaptan as a novel approach in patients with renal impairment and heart failure.
Methods: Two reviewers conducted a screening of articles using online databases, including PubMed, Google Scholar, and Embase.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!